There are currently patents and exclusivity rights in place that prevent any generic Tasigna (nilotinib) products from being manufactured in the United States. When the patent expires in July 2023, it's possible that generic versions could be introduced; however, circumstances could come up to delay the production of generic Tasigna, such as lawsuits or other patents for new uses of the drug.
Can I Buy Generic Tasigna?Tasigna® (nilotinib) is a prescription medication used in the treatment of leukemia. Specifically, it is used to treat a type of leukemia known as chronic myeloid leukemia (CML).
Tasigna is made by Novartis Pharma Stein AG for Novartis Pharmaceuticals Corporation. It is currently protected from generic competition by patents and exclusivity rights that have yet to expire.
When Will a Generic Version Be Available?The first patent for Tasigna expires in July 2023. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to extend or shorten this exclusivity period. This could include such things as lawsuits or other patents for new Tasigna uses. Once the drug goes off-patent, there may be several companies that manufacture a generic Tasigna drug.
Is Nilotinib a Generic Tasigna?No -- nilotinib is the active ingredient in Tasigna, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name." The generic name is different from a generic version of a medicine.
In order for there to be a generic version of a medicine, the original medicine must have gone off-patent, and another company besides the original manufacturer must make the product.